Middletown Life

Author: Telix Pharmaceuticals Limited

Telix Strengthens Board with Additional Director Appointments

April 8, 2026
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

April 7, 2026
Telix Appoints David Gill as Non-Executive Director

April 1, 2026
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

March 15, 2026
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

March 9, 2026
Investor Education Webinar

March 1, 2026
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging

February 27, 2026
Telix to Participate in Oppenheimer and TD Cowen Conferences

February 20, 2026
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

February 19, 2026
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

February 17, 2026